Interventions-Salmeterol (Serevent) (50 .Lg twice daily) or salbutamol (200 ,ug four times a day) randomised in the ratio of two patients taking salmeterol to one taking salbutamol. All other drugs including prophylaxis against asthma were continued throughout the study.
Main outcome measures-All serious events and reasons for withdrawals (medical and non-medical) whether or not they were considered to be related to the drugs.
Results-Fewer medical withdrawals due to asthma occurred in patients taking salmeterol than in those taking salbutamol (2-91% v 3 .79%; X2=13X6, p=00002). Mortality and admissions to hospital were as expected. There was a small but nonsignificant excess mortality in the group taking salmeterol and a significant excess of asthma events including deaths in patients with severe asthma on entry. Use ofmore than two canisters ofbronchodilator a month was particularly associated with the occurrence ofan adverse asthma event.
Conclusions-Treatment over 16 weeks with either salmeterol or salbutamol was not associated with an incidence of deaths related to asthma in excess of that predicted. Overall control of asthma was better in patients allocated to salmeterol. Serious adverse events occurred in patients most at risk on entry and were probably due to the disease rather than treatment.
Introduction
Inhaled X agonists are accepted as the most effective bronchodilators in current clinical use, although recently their use in treating asthma has been questioned.' 2 The questions do not relate to their use in relieving acute bronchospasm but rather to their use as maintenance treatment. 3 One study suggested that the control of asthma may be worse during treatment with regular fenoterol compared with intermittent 13 agonists.4 More recently the safety of ,B agonists has come under scrutiny. 5 Firstly, a rebound increase in bronchial reactivity has been observed in research that studied regular use of (3 agonists,6 although this has not been a consistent finding.7 Secondly, a reduction in lung function was reported during a two year study of salbutamol and ipratropium bromide,8 although again this has not been found in other studies. 9 In addition, epidemiological studies have shown an increase in deaths due to asthma, which some authors have related to the use of (3 agonists,'0 and a more detailed case control study has related increased use of ( agonists to an increased risk of death from asthma." For each additional canister administered each month the odds ratio increased by 2-6. Causal relations have been suggested but the high use of 1 agonists probably merely reflects severity of asthma and that these patients with more severe asthma are at greater risk of death. Such a relation between severe asthma and the risk of death has indeed been shown in other epidemiological studies. '2 The development of a long acting ( agonist'3 for which regular use is recommended has raised some concerns. Our study compared the safety of salmeterol (50 ,ug Serevent twice daily) with that of salbutamol (200 ,ug four times a day) in a large number of patients with asthma (> 25 000). Because of the large numbers we could compare our results with events related to asthma throughout the United Kingdom. '4 15 Subjects and methods
PROTOCOL
The trial was a randomised, double blind study in parallel groups over 16 weeks. Randomisation from blocks of six was four patients allocated to salmeterol (50 ,ug, two puffs morning and bedtime and two puffs of placebo noon and early evening to retain the blinding) to two patients allocated to salbutamol (200 pg, two puffs four times a day). The general practitioners were all given prenumbered treatment packs which they gave to the patients as they were allocated the next consecutive study number. All other drugs including prophylaxis against asthma was continued throughout the study. The supervising general practitioner was asked to prescribe whatever treatment he or she considered appropriate to relieve symptoms. The trial was conducted by 3516 Any patient could be withdrawn from the study at any time at the discretion of the investigator or the request of the patient, but the reason for doing so was required for each case. Whenever a patient was withdrawn from the study the investigator had to confirm that the patient remained alive at the end of the study.
Each serious adverse event or withdrawal form was forwarded promptly to the medical department, where its receipt was documented but the code not broken. The investigator was contacted by telephone or letter or visited if follow up information was required. Documentation from death certificates and postmortem examinations was obtained. The records were photocopied and sent to the intemational drug surveillance division of Glaxo Group Research, where the randomisation code was broken and the drug identity was recorded on the form. Access to the code was restricted to the people within the division who required the information to generate interim reports to regulatory authorities. For patients with adverse events falling into more than one category, deaths were given precedence over events meeting the regulatory definitions of serious, which in tum took precedence over withdrawals for minor medical reasons. If follow up information was received about a particular patient which materially altered the nature of the case or the outcome-for example, if a patient with a serious adverse event was later found to have died within the study period-this record on the database was updated to reflect the new information.
Events related to asthma were taken to include all asthmatic events irrespective of causality. Chest infections such as pneumonia, when no symptom of bronchospasm was reported, were categorised as respiratory but not related to asthma. Respiratory adverse events were defined according to ICD (ninth revision).
When patients were described as having an event in which different symptoms or diagnoses fell into different body systems, asthma as a cause was given precedence. Otherwise the event was counted against the classification of the body system of the most important symptom in the opinion of Glaxo physicians.
An independent review of the blinded data for deaths related or possibly related to asthma in both treatment groups was undertaken by three consultants selected by the National Asthma Campaign. An independent statistician received a copy of the interim tables forwarded to the regulatory authorities and gave independent statistical advice throughout. The standard (demographic) forms completed at entry and at four, eight, and 16 weeks were contracted out for data management and analysis by VAMP Research Ltd. Comparisons between the treatment groups were made by X2 test. The results are expressed as absolute incidence and relative risk between treatments. No formal power calculation on any specific event was made as the primary objective was to compare the incidence of all safety outcomes. The numbers in table I refer to the number of patients in whom full data were available. The larger numbers in table III refer to the total numbers randomised.
Results
There were 25 180 patients randomised to treatment, 16 787 to salmeterol and 8393 to salbutamol. All serious adverse event or withdrawal forms were entered and analysed. Randomised treatment groups according to entry criteria (table I) were well balanced *Many patients were taking more than one drug at entry.
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at entry for demography, severity of a: treatment, and concomitant diseases. Si) cent were taking inhaled steroids, 4-7% c and 977% had used three or more canisters inhalers in the four weeks before recruitme The requirement for the use of ( agonist to the severity of asthma, with the numbe month being 1-2 for mild asthma, 1-5 fc and 2-0 for severe in both groups. Of considered to be mildly asthmatic 1-2% oral and 45% inhaled steroids; the figures N 72% in those with moderate asthma and 1 in those with severe asthma. Table III summarises all deaths, serious events, and xty nine per withdrawals, whose incidences were similar between )ral steroids, the two groups. The only significant difference was the of (3 agonist numbers of medical withdrawals due to asthma, which nt (table II) . were fewer with salmeterol than with salbutamol :s was related (2-91% v 3-79%, x2= 13-6; p=0-0002 Comparison of the reported events shows that the only significant differences were the number of medical withdrawals due to asthma, fewer occurring with salmeterol (2 9 10% v 3 79%). The relative benefits of treatment can be inferred to some degree from the rate of withdrawal. None of the other events in this trial approached differences which were significant, the study being sized appropriately and of adequate duration to detect a clinically meaningful difference.
There was a numerical excess of deaths in the salmeterol group: 0 07% compared with 0-02%, a relative risk of 3. The numbers were very small, however, and the confidence interval of this risk was wide; the difference was therefore not significant. Is the difference then a chance finding? Obviously we cannot answer this, although a number of points need to be considered. The overall number of deaths (14) is in line with that which would have been expected of a sample of patients with asthma of this size in the United Kingdom-that is, 15.14 15 This comparison would be valid only if the distribution of severe asthma in the study population was at least as great as that in the general population. The patients recruited to the study did not predominantly have mild asthma; 17% were classified by their general practitioners as having severe asthma at entry, 69% were taking inhaled steroids, 4.7% were taking oral steroids, 9 5% had used three or more canisters of ,B agonist inhalers during the four weeks before the study, and, of course, all had a clinical requirement for regular bronchodilator treatment. As a comparison, in 1990 52% ofadults with asthma were issued with at least one prescription for an inhaled steroid, 3% were given oral steroids for a full 12 months as maintenance treatment (5*1% at some time during the year), and 3-4% were issued with three or more ,B agonist inhalers each month (AAH Meditel UK, unpublished data). Therefore the mortality was not biased because the study recruited patients with mild asthma. In addition, there was no detectable pattern in the deaths related to asthma which occurred in patients deemed by the independent assessors to have severe asthma. Also other events related to asthma showed no trend towards being worse with salmeterol than salbutamol. In fact, the only significant difference in the entire study was the opposite.
Previous much smaller studies such as those described by Sears et aP and van Schayck et at described an apparent deterioration in asthma, albeit over a longer treatment period. Our data are not consistent with this as the overall rates of death and admission to hospital were not excessive, and patients with mild and moderate asthma were not put at equal risk by the use of the 1B agonist as were those with severe asthma. The problem of deaths from asthma and severe events is therefore one of undertreatment of asthma rather than regular use of ,B agonists. As the independent reviewers suggested that the asthma might have been more appropriately treated by earlier or higher doses of glucocorticosteroids in at least 10 of the patients in the study who died, it is appropriate to strengthen the recommendations of how best to treat severe asthma. Glaxo has therefore altered all its data sheets for drugs used to treat asthma, both 1 agonists and inhaled corticosteroids, to improve the information to doctors on the treatment of the disease, especially when it is severe or unstable. This study clearly indicates such patients are at risk.
We suggest that patients with severe and/or unstable asthma are at potential risk of dying from the disease. Use of high doses (two or more canisters a month) of 13 agonists is not appropriate as the main or only treatment and is related to severity of disease. Such patients require stabilisation of their asthma with appropriate doses of inhaled or oral glucocorticosteroids (> 1 mg per day of beclomethasone dipropionate or equivalent) as their main treatment.
